Biological activity of inorganic arsenic and antimony reflects oxidation state in cultured human keratinocytes.
Sodium arsenite is much more potent than sodium arsenate in producing adverse effects in animals and in cultured cells. Although arsenate may exhibit toxicity as a phosphate analogue, its potency in vivo appears to be enhanced by reduction to arsenite. To understand the relative importance of this reduction, which is critical in evaluating the responsiveness of cell culture models to the different oxidation states and thus to elucidating the mechanism of arsenic action, present work has correlated the extent of reduction with biological activity in human keratinocytes. The results show that at biologically relevant concentrations, arsenate reduction to appreciable levels required several days, helping rationalize a previous empirical observation that it was approximately one-third as potent as arsenite. The relatively low conversion rate also emphasizes a limitation of culture; arsenate was nearly as efficacious as arsenite, but the time required for it to reach maximal effect exceeded ordinary medium change intervals. In keratinocytes, an important role for purine nucleoside phosphorylase in the reduction could not be demonstrated, indicating that another pathway is dominant in this cell type. Methylation of inorganic arsenic, uptake of methylated forms, and their reduction were all very slow. These findings suggest that the reduced methylated forms have only a small contribution to skin carcinogenesis unless they are supplied through the circulation. In parallel experiments, trivalent antimony was similar to arsenite in potency and efficacy, whereas pentavalent antimony was virtually without biological effect. Conversion of antimony in the pentavalent to the trivalent oxidation state was not detectable in keratinocytes. These findings emphasize the importance of intracellular reduction of the metalloids for biological effects.
Patterson
Timothy J
TJ
Departments of Environmental Toxicology and Civil and Environmental Engineering, University of California, Davis, California 95616, USA.
Ngo
Mai
M
Aronov
Pavel A
PA
Reznikova
Tatiana V
TV
Green
Peter G
PG
Rice
Robert H
RH
D000818:Animals; D000965:Antimony / Q000737:chemistry* / Q000493:pharmacokinetics / Q000633:toxicity*; D001151:Arsenic / Q000737:chemistry* / Q000493:pharmacokinetics / Q000633:toxicity*; D001711:Biotransformation; D002417:Cattle; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004790:Enzyme Induction / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005347:Fibroblasts / Q000378:metabolism; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006419:Heme Oxygenase (Decyclizing) / Q000378:metabolism; D051547:Heme Oxygenase-1; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008565:Membrane Proteins; D010084:Oxidation-Reduction; D011498:Protein Precursors / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D011684:Purine Nucleosides; D011683:Purine-Nucleoside Phosphorylase / Q000037:antagonists & inhibitors / Q000378:metabolism; D011744:Pyrimidinones / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D013154:Spleen / Q000201:enzymology
D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D011498:Protein Precursors; D011684:Purine Nucleosides; D011744:Pyrimidinones; D011758:Pyrroles; C113101:forodesine; D006147:Guanine; C032253:involucrin; C104194:peldesine; D000965:Antimony; C496541:HMOX1 protein, human; D006419:Heme Oxygenase (Decyclizing); D051547:Heme Oxygenase-1; D011683:Purine-Nucleoside Phosphorylase; D001151:Arsenic